umu.sePublications
Change search
ReferencesLink to record
Permanent link

Direct link
Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine.
2016 (English)In: Expert Review of Vaccines, ISSN 1476-0584, E-ISSN 1744-8395, Vol. 15, no 4Article in journal (Refereed) Published
Abstract [en]

CYD-TDV is the first dengue vaccine to have completed Phase 3 efficacy trials. Efficacy was consistently higher in those aged 9 and above for all variables studied: efficacy against virologically confirmed dengue of any severity and serotype, serotype specific efficacy, efficacy dependent on baseline seropositivity, efficacy against hospitalizations and efficacy against severe disease. Because of the higher efficacy and the absence of a safety signal, the age group with the best benefit of the use of CYD-TDV is individuals aged 9 and above - the age group for which licensure is now being sought.

Place, publisher, year, edition, pages
2016. Vol. 15, no 4
National Category
Public Health, Global Health, Social Medicine and Epidemiology
Identifiers
URN: urn:nbn:se:umu:diva-127481DOI: 10.1586/14760584.2016.1143366PubMedID: 26775653OAI: oai:DiVA.org:umu-127481DiVA: diva2:1046480
Available from: 2016-11-14 Created: 2016-11-14 Last updated: 2016-11-14

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wilder-Smith, Annelies
In the same journal
Expert Review of Vaccines
Public Health, Global Health, Social Medicine and Epidemiology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

ReferencesLink to record
Permanent link

Direct link